<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>4(2)</volume><submitter>Foster PD</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Recently, several new atypical antipsychotic agents have been introduced in Ontario, and regulatory warnings have been issued regarding use of atypical antipsychotics in older adults. We sought to establish the impact of newer atypical antipsychotics on prescribing rates and costs.&lt;h4>Methods&lt;/h4>We performed a population-based cross-sectional study of Ontario adults aged 65 years or more using atypical antipsychotics from Jan. 1, 2007, to Mar. 31, 2013. These people have universal access to publicly funded drugs through the Ontario Health Insurance Plan and the Ontario Drug Benefit. We conducted time-series analysis to assess the impact of the introduction of new atypical antipsychotics on rates of use of atypical antipsychotics and associated expenditures.&lt;h4>Results&lt;/</pubmed_abstract><journal>CMAJ open</journal><pagination>E292-7</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4933600</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Trends in the use and cost of antipsychotics among older adults from 2007 to 2013: a repeated cross-sectional study.</pubmed_title><pmcid>PMC4933600</pmcid><pubmed_authors>Yao Z</pubmed_authors><pubmed_authors>Gomes T</pubmed_authors><pubmed_authors>Foster PD</pubmed_authors><pubmed_authors>Paterson JM</pubmed_authors><pubmed_authors>Mamdani MM</pubmed_authors><pubmed_authors>Martins D</pubmed_authors><pubmed_authors>Vigod S</pubmed_authors><pubmed_authors>Camacho X</pubmed_authors><pubmed_authors>Juurlink DN</pubmed_authors></additional><is_claimable>false</is_claimable><name>Trends in the use and cost of antipsychotics among older adults from 2007 to 2013: a repeated cross-sectional study.</name><description>&lt;h4>Background&lt;/h4>Recently, several new atypical antipsychotic agents have been introduced in Ontario, and regulatory warnings have been issued regarding use of atypical antipsychotics in older adults. We sought to establish the impact of newer atypical antipsychotics on prescribing rates and costs.&lt;h4>Methods&lt;/h4>We performed a population-based cross-sectional study of Ontario adults aged 65 years or more using atypical antipsychotics from Jan. 1, 2007, to Mar. 31, 2013. These people have universal access to publicly funded drugs through the Ontario Health Insurance Plan and the Ontario Drug Benefit. We conducted time-series analysis to assess the impact of the introduction of new atypical antipsychotics on rates of use of atypical antipsychotics and associated expenditures.&lt;h4>Results&lt;/</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Apr-Jun</publication><modification>2025-04-22T02:15:20.654Z</modification><creation>2019-03-27T02:17:38Z</creation></dates><accession>S-EPMC4933600</accession><cross_references><pubmed>27398376</pubmed><doi>10.9778/cmajo.20150095</doi></cross_references></HashMap>